C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

C4 Therapeutics, Inc.NASDAQ: CCCC

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2.67M fell 51.5% year over year, behind the -43.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 33.3% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.

Context

  • Stock-based compensation amounted to 53.1% of revenue in FY2025, down 30.2 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -51.5% toward the trailing-twelve-month pace of -43.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.67M-33.3% QoQ
Last fiscal yearDec 2025
$19.1M-35.6% YoY
LTMMar 2026
$16.26M-43.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-51.5%——
1 year-35.6%——
3-year CAGR-14.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
19.1M USD
Year-over-year change
-35.6%
4-year CAGR
-2.9%

Stock-Based Compensation vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -43.8% is the lowest of 9, against a peer median of -14.8%.
  • Stock-based compensation amounts to 46.7% of revenue for CCCC, versus a peer median of 75.1%.
CCCC Competitors
Stock-Based Compensation for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CCCCC4 Therapeutics, Inc.LTM Mar 2026$16.26M USD-43.8%-14.0%46.7%
OABIOmniAb, Inc.LTM Mar 2026$15.02M USD-24.7%-4.8%52.0%
PEPGPepGen Inc.LTM Mar 2026$10.03M USD-22.0%+30.6%—
CDXSCodexis, Inc.LTM Mar 2026$8.67M USD-29.5%-12.8%11.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$7.48M USD-39.0%-34.0%21.6%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$6.14M USD+9.4%-6.2%344.3%
MOLNMolecular Partners AGLTM Mar 2026CHF 4.21M CHF-4.1%-4.6%—
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.9M USD-7.5%-5.6%98.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$2.4M USD+50.7%-39.5%123.1%
Peer median (excluding CCCC) —-14.8%-5.9%75.1%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Depreciation & Amortization1.49M1.68M1.88M1.82M1.96M
Deferred Income Tax1.88M0000
Stock-Based Compensation21.51M30.02M27.24M29.66M19.1M
Change in Working Capital(30.09M)(16.78M)(6.94M)7.65M(29.28M)
Accounts Receivables(1.23M)4.24M(10.33M)8.7M701K
Inventory(2.63M)0000
Accounts Payables(1.18M)(3.33M)273K(119K)(468K)
Other Working Capital(25.05M)(17.69M)3.12M(930K)(29.52M)
Other Non-Cash Items2.13M7.32M3.48M1.03M14.52M
Operating Cash Flow(86.97M)(105.94M)(106.84M)(65.16M)(98.69M)
Capital Expenditures(1.28M)(5.5M)(1.71M)(180K)(607K)
Acquisitions (Net)188.06M(63.92M)000
Purchases of Investments(537.74M)(219.53M)(129.9M)(284.32M)(227.07M)
Sales of Investments349.68M283.45M289.96M233.23M219.08M
Other Investing Activities(188.06M)63.92M000
Investing Cash Flow(189.34M)58.42M158.35M(51.27M)(8.6M)
Debt Repayment00(12.5M)00
Common Stock Issued169.47M777K57.67M44.37M126.32M
Common Stock Repurchased00(110K)(194K)(193K)
Dividends Paid00000
Other Financing Activities1.94M370K426K1.16M274K
Financing Cash Flow171.4M1.15M45.49M45.34M126.4M
Effect of Forex Changes00000
Net Change in Cash(104.9M)(46.37M)97M(71.09M)19.1M
Free Cash Flow(88.24M)(111.44M)(108.55M)(65.34M)(99.3M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.